These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 27317186)
1. Incorporation of Heterologous Proteins in Engineered Exosomes. Manfredi F; Di Bonito P; Arenaccio C; Anticoli S; Federico M Methods Mol Biol; 2016; 1448():249-60. PubMed ID: 27317186 [TBL] [Abstract][Full Text] [Related]
2. A strategy of antigen incorporation into exosomes: comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles. Lattanzi L; Federico M Vaccine; 2012 Nov; 30(50):7229-37. PubMed ID: 23099330 [TBL] [Abstract][Full Text] [Related]
3. Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation. Di Bonito P; Chiozzini C; Arenaccio C; Anticoli S; Manfredi F; Olivetta E; Ferrantelli F; Falcone E; Ruggieri A; Federico M Int J Nanomedicine; 2017; 12():4579-4591. PubMed ID: 28694699 [TBL] [Abstract][Full Text] [Related]
4. The Intracellular Delivery Of Anti-HPV16 E7 scFvs Through Engineered Extracellular Vesicles Inhibits The Proliferation Of HPV-Infected Cells. Ferrantelli F; Arenaccio C; Manfredi F; Olivetta E; Chiozzini C; Leone P; Percario Z; Ascione A; Flego M; Di Bonito P; Accardi L; Federico M Int J Nanomedicine; 2019; 14():8755-8768. PubMed ID: 31806970 [TBL] [Abstract][Full Text] [Related]
7. Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Sistigu A; Bracci L; Valentini M; Proietti E; Bona R; Negri DR; Ciccaglione AR; Tritarelli E; Nisini R; Equestre M; Costantino A; Marcantonio C; Santini SM; Lapenta C; Donati S; Tataseo P; Miceli M; Cara A; Federico M Vaccine; 2011 Apr; 29(18):3465-75. PubMed ID: 21382480 [TBL] [Abstract][Full Text] [Related]
8. Microglia-derived HIV Nef+ exosome impairment of the blood-brain barrier is treatable by nanomedicine-based delivery of Nef peptides. Raymond AD; Diaz P; Chevelon S; Agudelo M; Yndart-Arias A; Ding H; Kaushik A; Jayant RD; Nikkhah-Moshaie R; Roy U; Pilakka-Kanthikeel S; Nair MP J Neurovirol; 2016 Apr; 22(2):129-39. PubMed ID: 26631079 [TBL] [Abstract][Full Text] [Related]
9. Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1. Arenaccio C; Anticoli S; Manfredi F; Chiozzini C; Olivetta E; Federico M Retrovirology; 2015 Oct; 12():87. PubMed ID: 26502902 [TBL] [Abstract][Full Text] [Related]
17. Exosomes in HIV infection: A review and critical look. Ellwanger JH; Veit TD; Chies JAB Infect Genet Evol; 2017 Sep; 53():146-154. PubMed ID: 28546080 [TBL] [Abstract][Full Text] [Related]
18. Engineering exosomes for targeted drug delivery. Liang Y; Duan L; Lu J; Xia J Theranostics; 2021; 11(7):3183-3195. PubMed ID: 33537081 [TBL] [Abstract][Full Text] [Related]
19. Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells. Marusic C; Nuttall J; Buriani G; Lico C; Lombardi R; Baschieri S; Benvenuto E; Frigerio L BMC Biotechnol; 2007 Feb; 7():12. PubMed ID: 17324250 [TBL] [Abstract][Full Text] [Related]
20. Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection. de Carvalho JV; de Castro RO; da Silva EZ; Silveira PP; da Silva-Januário ME; Arruda E; Jamur MC; Oliver C; Aguiar RS; daSilva LL PLoS One; 2014; 9(11):e113691. PubMed ID: 25423108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]